ArticleHuman mutation2026
Use of Single-Cell Data and scPagwas Analysis to Identify T Cell Subsets and Construct a Prognostic Model for Clear Cell Renal Cell Carcinoma.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clear cell renal cell carcinoma (KIRC), the most prevalent pathological renal cell carcinoma (RCC) subtype, makes up approximately 75%-84% of total cases. KIRC is characterized by high heterogeneity, high metastasis rates, and a poor prognosis. Its incidence rate has continued to rise in recent years. We sought to construct new prognostic models to optimize treatment decisions, improve clinical benefits, and explore potential therapeutic targets. Methods: This study integrated various omics data including single-cell RNA seq (GSE171306), TCGA-KIRC, GWAS, and validation datasets (GSE29609 and E-MTAB-1980). The scPagwas algorithm combines GWAS with scRNA-seq to identify immune subgroups with high feature correlation. Key genes are identified through the combination of weighted correlation network analysis (WGCNA) with differentially expressed genes (DEGs). We built a clinical prognostic model by using machine learning algorithms and validated it through survival rate and receiver operating characteristic (ROC) analysis. We used cancer drug sensitivity genomics data to analyze drug sensitivity and performed molecular docking to identify potential therapeutic drugs. Results: Using single-cell RNA seq data, we identified T cell subsets as characteristic cell subsets in KIRC through scPagwas analysis. In single-cell analysis, key genes in T cell subsets and genes with PCC values > 0.05 were combined with the core genes in DEGs and WGCNA modules, thus yielding 86 intersecting genes. These genes were significantly enriched in immune-related pathways. We established a clinical prognostic model containing seven risk genes. Low-risk patients exhibited substantial survival advantages. Time-dependent ROC analysis indicated the prognostic model's excellent clinical predictive value. Functional enrichment, immune infiltration, and somatic mutation analyses highlighted different biological mechanisms among risk populations. The SHAP values of the XGBoost and LightGBM machine learning algorithms indicated DOCK8 as a potential biomarker. Drug prediction and molecular docking predicted five potential drugs targeting DOCK8 (finasteride, nocodazole, palonosetron, pifithrin alpha, and topiramate). Conclusion: Our systematic analysis of the immune microenvironment, key genes, and prognosis of KIRC highlighted the critical roles of T cell subsets. We additionally established an effective clinical prognostic model. Our findings provide new insights and potential targets for the precise diagnosis and targeted KIRC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.